Coley's Toxins and the Origins of Immunotherapy
Summary
This episode explores the history of cancer immunotherapy, focusing on William B. Coley’s late 19th-century experiments using bacterial toxins to treat sarcomas. After the tragic death of a young patient, Coley developed "Coley’s Toxins," which showed mixed results and faced significant scientific criticism before being largely abandoned due to the rise of radiation therapy. The hosts discuss how Coley’s work laid the groundwork for modern immunology, leading to the discovery of tumor necrosis factor and the FDA-approved use of BCG for bladder cancer.
Topics discussed
Sponsorships and show introduction
Melanoma vaccine news and immunotherapy context
Early immunotherapy history and William B. Coley's background
The case of Bessie Dashell and its impact on Coley
Discovery of erysipelas effect on tumors and early trials
Sponsor breaks and transition to Rockefeller's involvement
Shifting from live bacteria to bacterial toxins
Coley's theories on cancer origin and treatment criteria
Medical community criticism and Coley's defense
Sponsor breaks and return to Coley's later work
Mixed toxins, B. prodigiosus, and conflict with James Ewing
Regulatory hurdles and the 1934 AMA statement
Helen Coley's research and the Cancer Research Institute
BCG vaccine development and FDA classification of toxins
Modern clinical trials of Coley's toxins
Listener mail: Anne Bonny short film story
Outro and final sponsorships
Listen ad-free on Castria